✦ LIBER ✦

PDB9 LONG-TERM CLINICAL OUTCOMES OF EXENATIDE ONCE-WEEKLY VERSUS INSULIN GLARGINE FOR THE TREATMENT OF TYPE 2 DIABETES PROJECTED USING THE CORE DIABETES MODEL

✍ Scribed by L Timlin; A Beaudet; B Wilson; D Bruhn; KS Boye; JL Palmer; A Lloyd

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PDB26 Projected Long-Term Clinical and E

✍ Beaudet, A.; Wilson, B.; Caputo, J.; Timlin, L. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PDB14 USING HEALTH OUTCOMES MODELING TO

✍ L. Garrison; J.H. Best; J.C. Robertson; M. Wenten; D. Bruhn 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB

PDB27 Projected Cost-Effectiveness of Ex

✍ Wilson, B.P.; Beaudet, A.; Caputo, J.; Timlin, L. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PDB27 COST-EFFECTIVENESS OF EXENATIDE VE

✍ D Bruhn; S Malhan; S Kavuncubasi; J Smith-Palmer; V Reed 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

PDB51 COST-EFFECTIVENESS OF EXENATIDE VE

✍ JL Palmer; CG Pinto; R Duarte; L Miguel; Z Gregor 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

PDB36 LONG-TERM COST-CONSEQUENCE ANALYSI

✍ Gaebler J Aledort; Y Samyshkin; ALG Guillermin; A Lloyd 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB